_id
690db3afccc777a4e85d0cfc
Ticker
AVNS
Name
Avanos Medical Inc
Exchange
NYSE
Address
5405 Windward Parkway, Alpharetta, GA, United States, 30004
Country
USA
Sector
Healthcare
Industry
Medical Devices
Currency
USD
Website
https://avanos.com
Description
Avanos Medical, Inc., a medical technology company, provides medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides non-opioid pain solutions, including surgical pain and recovery products, which comprise ON-Q and ambIT surgical pain pump, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which provide minimally invasive pain-relieving therapies, such as COOLIEF chronic pain products; OrthogenRx knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. The company markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Last Close
11.75
Volume
602492
Current Price
11.86
Change
0.9361702127659527
Last Updated
2025-11-28T12:35:56.598Z
Image
data:image/webp;base64,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
Ipo Date
2014-10-21T00:00:00.000Z
Market Cap
549599872
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.9966666666666667
Sentiment Sources
3
Rating
3
Target Price
14
Strong Buy
0
Buy
0
Hold
1
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
177800000
Cost Of Revenue
96700000
Gross Profit
81100000
Operating Expenses
68000000
Operating Income
13100000
Interest Expense
1800000
Pretax Income
-1200000
Net Income
-1400000
Eps
-0.03017241379310345
Dividends Per Share
-
Shares Outstanding
46418907
Income Tax Expense
200000
EBITDA
10000000
Operating Margin
7.367829021372328
Total Other Income Expense Net
-14300000
Cash
70500000
Short Term Investments
-
Receivables
111300000
Inventories
150600000
Total Current Assets
351400000
Property Plant Equipment
145300000
Total Assets
1067700000
Payables
54200000
Short Term Debt
18900000
Long Term Debt
93400000
Total Liabilities
289700000
Equity
778000000
Depreciation
9400000
Change In Working Capital
-2900000
Cash From Operations
14000000
Capital Expenditures
7000000
Cash From Investing
-31500000
Cash From Financing
-2000000
Net Change In Cash
-19800000
PE
-
PB
0.707331619537275
ROE
-0.17994858611825193
ROA
-0.13112297461833847
FCF
7000000
Fcf Percent
0.03937007874015748
Piotroski FScore
2
Health Score
37
Deep Value Investing Score
7
Defensive Investing Score
7
Dividend Investing Score
3
Economic Moat Investing Score
6.3
Garp Investing Score
4
Growth Investing Score
2.5
Momentum Investing Score
3
Net Net Investing Score
2.5
Quality Investing Score
6
Value Investing Score
5.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
177800000
Quarters > 0 > income Statement > cost Of Revenue
96700000
Quarters > 0 > income Statement > gross Profit
81100000
Quarters > 0 > income Statement > operating Expenses
68000000
Quarters > 0 > income Statement > operating Income
13100000
Quarters > 0 > income Statement > interest Expense
1800000
Quarters > 0 > income Statement > pretax Income
-1200000
Quarters > 0 > income Statement > net Income
-1400000
Quarters > 0 > income Statement > eps
-0.03017241379310345
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
46400000
Quarters > 0 > income Statement > income Tax Expense
200000
Quarters > 0 > income Statement > EBITDA
10000000
Quarters > 0 > income Statement > operating Margin
7.367829021372328
Quarters > 0 > income Statement > total Other Income Expense Net
-14300000
Quarters > 0 > balance Sheet > cash
70500000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
111300000
Quarters > 0 > balance Sheet > inventories
150600000
Quarters > 0 > balance Sheet > total Current Assets
351400000
Quarters > 0 > balance Sheet > property Plant Equipment
145300000
Quarters > 0 > balance Sheet > total Assets
1067700000
Quarters > 0 > balance Sheet > payables
54200000
Quarters > 0 > balance Sheet > short Term Debt
18900000
Quarters > 0 > balance Sheet > long Term Debt
93400000
Quarters > 0 > balance Sheet > total Liabilities
289700000
Quarters > 0 > balance Sheet > equity
778000000
Quarters > 0 > cash Flow > net Income
-1400000
Quarters > 0 > cash Flow > depreciation
9400000
Quarters > 0 > cash Flow > change In Working Capital
-2900000
Quarters > 0 > cash Flow > cash From Operations
14000000
Quarters > 0 > cash Flow > capital Expenditures
7000000
Quarters > 0 > cash Flow > cash From Investing
-31500000
Quarters > 0 > cash Flow > cash From Financing
-2000000
Quarters > 0 > cash Flow > net Change In Cash
-19800000
Quarters > 0 > ratios > PE
-0.03017241379310345
Quarters > 0 > ratios > PB
0.707331619537275
Quarters > 0 > ratios > ROE
-0.17994858611825193
Quarters > 0 > ratios > ROA
-0.13112297461833847
Quarters > 0 > ratios > FCF
7000000
Quarters > 0 > ratios > Piotroski FScore
2
Quarters > 0 > ratios > fcf Percent
0.03937007874015748
Quarters > 0 > health Score
37
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
175000000
Quarters > 1 > income Statement > cost Of Revenue
82900000
Quarters > 1 > income Statement > gross Profit
92100000
Quarters > 1 > income Statement > operating Expenses
84800000
Quarters > 1 > income Statement > operating Income
7300000
Quarters > 1 > income Statement > interest Expense
2000000
Quarters > 1 > income Statement > pretax Income
-75900000
Quarters > 1 > income Statement > net Income
-76800000
Quarters > 1 > income Statement > eps
-1.641025641025641
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
46800000
Quarters > 1 > income Statement > income Tax Expense
900000
Quarters > 1 > income Statement > EBITDA
-63900000
Quarters > 1 > income Statement > operating Margin
4.171428571428572
Quarters > 1 > income Statement > total Other Income Expense Net
-83200000
Quarters > 1 > balance Sheet > cash
90300000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
110200000
Quarters > 1 > balance Sheet > inventories
142700000
Quarters > 1 > balance Sheet > total Current Assets
356000000
Quarters > 1 > balance Sheet > property Plant Equipment
145400000
Quarters > 1 > balance Sheet > total Assets
1039000000
Quarters > 1 > balance Sheet > payables
48800000
Quarters > 1 > balance Sheet > short Term Debt
19800000
Quarters > 1 > balance Sheet > long Term Debt
95700000
Quarters > 1 > balance Sheet > total Liabilities
262700000
Quarters > 1 > balance Sheet > equity
776300000
Quarters > 1 > cash Flow > net Income
-76800000
Quarters > 1 > cash Flow > depreciation
10000000
Quarters > 1 > cash Flow > change In Working Capital
-6800000
Quarters > 1 > cash Flow > cash From Operations
6800000
Quarters > 1 > cash Flow > capital Expenditures
11000000
Quarters > 1 > cash Flow > cash From Investing
-13200000
Quarters > 1 > cash Flow > cash From Financing
-3200000
Quarters > 1 > cash Flow > net Change In Cash
-6700000
Quarters > 1 > ratios > PE
-1.641025641025641
Quarters > 1 > ratios > PB
0.7149916269483446
Quarters > 1 > ratios > ROE
-9.893082571170938
Quarters > 1 > ratios > ROA
-7.391722810394611
Quarters > 1 > ratios > FCF
-4200000
Quarters > 1 > ratios > Piotroski FScore
2
Quarters > 1 > ratios > fcf Percent
-0.024
Quarters > 1 > health Score
35
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
167500000
Quarters > 2 > income Statement > cost Of Revenue
77700000
Quarters > 2 > income Statement > gross Profit
89800000
Quarters > 2 > income Statement > operating Expenses
82500000
Quarters > 2 > income Statement > operating Income
7300000
Quarters > 2 > income Statement > interest Expense
2100000
Quarters > 2 > income Statement > pretax Income
9700000
Quarters > 2 > income Statement > net Income
6600000
Quarters > 2 > income Statement > eps
0.14102564102564102
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
46800000
Quarters > 2 > income Statement > income Tax Expense
3100000
Quarters > 2 > income Statement > EBITDA
21400000
Quarters > 2 > income Statement > operating Margin
4.358208955223881
Quarters > 2 > income Statement > total Other Income Expense Net
2400000
Quarters > 2 > balance Sheet > cash
97000000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
104800000
Quarters > 2 > balance Sheet > inventories
138100000
Quarters > 2 > balance Sheet > total Current Assets
352400000
Quarters > 2 > balance Sheet > property Plant Equipment
141900000
Quarters > 2 > balance Sheet > total Assets
1107800000
Quarters > 2 > balance Sheet > payables
46000000
Quarters > 2 > balance Sheet > short Term Debt
19800000
Quarters > 2 > balance Sheet > long Term Debt
98000000
Quarters > 2 > balance Sheet > total Liabilities
268400000
Quarters > 2 > balance Sheet > equity
839400000
Quarters > 2 > cash Flow > net Income
6600000
Quarters > 2 > cash Flow > depreciation
9600000
Quarters > 2 > cash Flow > change In Working Capital
5400000
Quarters > 2 > cash Flow > cash From Operations
25700000
Quarters > 2 > cash Flow > capital Expenditures
6700000
Quarters > 2 > cash Flow > cash From Investing
-9100000
Quarters > 2 > cash Flow > cash From Financing
-29100000
Quarters > 2 > cash Flow > net Change In Cash
-10700000
Quarters > 2 > ratios > PE
0.14102564102564102
Quarters > 2 > ratios > PB
0.6612437455325233
Quarters > 2 > ratios > ROE
0.7862759113652609
Quarters > 2 > ratios > ROA
0.5957754107239575
Quarters > 2 > ratios > FCF
19000000
Quarters > 2 > ratios > Piotroski FScore
4
Quarters > 2 > ratios > fcf Percent
0.11343283582089553
Quarters > 2 > health Score
61
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
179600000
Quarters > 3 > income Statement > cost Of Revenue
80300000
Quarters > 3 > income Statement > gross Profit
99300000
Quarters > 3 > income Statement > operating Expenses
86800000
Quarters > 3 > income Statement > operating Income
12500000
Quarters > 3 > income Statement > interest Expense
2800000
Quarters > 3 > income Statement > pretax Income
-420500000
Quarters > 3 > income Statement > net Income
-397300000
Quarters > 3 > income Statement > eps
-8.63695652173913
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
46000000
Quarters > 3 > income Statement > income Tax Expense
-23500000
Quarters > 3 > income Statement > EBITDA
-406600000
Quarters > 3 > income Statement > operating Margin
6.959910913140312
Quarters > 3 > income Statement > total Other Income Expense Net
-433000000
Quarters > 3 > balance Sheet > cash
107700000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
132800000
Quarters > 3 > balance Sheet > inventories
138800000
Quarters > 3 > balance Sheet > total Current Assets
393400000
Quarters > 3 > balance Sheet > property Plant Equipment
144800000
Quarters > 3 > balance Sheet > total Assets
1154200000
Quarters > 3 > balance Sheet > payables
54300000
Quarters > 3 > balance Sheet > short Term Debt
20300000
Quarters > 3 > balance Sheet > long Term Debt
125300000
Quarters > 3 > balance Sheet > total Liabilities
325700000
Quarters > 3 > balance Sheet > equity
828500000
Quarters > 3 > cash Flow > net Income
-397300000
Quarters > 3 > cash Flow > depreciation
11100000
Quarters > 3 > cash Flow > change In Working Capital
45000000
Quarters > 3 > cash Flow > cash From Operations
57900000
Quarters > 3 > cash Flow > capital Expenditures
4800000
Quarters > 3 > cash Flow > cash From Investing
-7600000
Quarters > 3 > cash Flow > cash From Financing
-27400000
Quarters > 3 > cash Flow > net Change In Cash
18700000
Quarters > 3 > ratios > PE
-8.63695652173913
Quarters > 3 > ratios > PB
0.6584912492456246
Quarters > 3 > ratios > ROE
-47.95413397706699
Quarters > 3 > ratios > ROA
-34.42211055276382
Quarters > 3 > ratios > FCF
53100000
Quarters > 3 > ratios > Piotroski FScore
2
Quarters > 3 > ratios > fcf Percent
0.29565701559020047
Quarters > 3 > health Score
53
Valuation > metrics > PE
-0.03017241379310345
Valuation > metrics > PB
0.707331619537275
Valuation > final Score
70
Valuation > verdict
29.3% Undervalued
Profitability > metrics > ROE
-0.17994858611825193
Profitability > metrics > ROA
-0.398406374501992
Profitability > metrics > Net Margin
-0.007874015748031496
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.3723650385604113
Risk > metrics > Interest Coverage
7.277777777777778
Risk > final Score
89
Risk > verdict
Low
Liquidity > metrics > Current Ratio
4.807113543091655
Liquidity > metrics > Quick Ratio
2.746922024623803
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
70
Prev Valuations > 1
90
Prev Valuations > 2
70
Prev Profitabilities > 0
0
Prev Profitabilities > 1
13
Prev Profitabilities > 2
0
Prev Risks > 0
75
Prev Risks > 1
74
Prev Risks > 2
78
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-16T22:26:03.334Z
Avanos Medical, Inc., a medical technology company, provides medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides non-opioid pain solutions, including surgical pain and recovery products, which comprise ON-Q and ambIT surgical pain pump, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which provide minimally invasive pain-relieving therapies, such as COOLIEF chronic pain products; OrthogenRx knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. The company markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Stock Price
$ 0.00
0% increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AMulti Factor Analysis Ranks ANI Integrated Services Limited as Strong Buy - Mid Cap Growth Trends & Low Cost Portfolio Growth Bollywood Helpline
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
HOLD
Target Price:
$14
Analyst Picks
Strong Buy
0
Buy
0
Hold
1
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 72.92% of the total shares of Avanos Medical Inc
1.
BlackRock Inc(14.7176%)
since
2025/06/30
2.
Vanguard Group Inc(9.6221%)
since
2025/06/30
3.
T. Rowe Price Investment Management,Inc.(8.6127%)
since
2025/06/30
4.
Dimensional Fund Advisors, Inc.(5.5559%)
since
2025/06/30
5.
Armistice Capital, LLC(4.3877%)
since
2025/06/30
6.
State Street Corp(4.1324%)
since
2025/06/30
7.
Brown Advisory Holdings Inc(3.8981%)
since
2025/06/30
8.
Paradice Investment Management LLC(2.7107%)
since
2025/06/30
9.
ExodusPoint Capital Management, LP(2.6894%)
since
2025/06/30
10.
D. E. Shaw & Co LP(2.5687%)
since
2025/06/30
11.
Geode Capital Management, LLC(2.3146%)
since
2025/06/30
12.
Morgan Stanley - Brokerage Accounts(1.8502%)
since
2025/06/30
13.
Tributary Capital Management, LLC(1.7471%)
since
2025/06/30
14.
Charles Schwab Investment Management Inc(1.4321%)
since
2025/06/30
15.
Qube Research & Technologies(1.3478%)
since
2025/06/30
16.
AQR Capital Management LLC(1.2069%)
since
2025/06/30
17.
Clark Estates Inc(1.0643%)
since
2025/06/30
18.
Northern Trust Corp(1.0562%)
since
2025/06/30
19.
Pacer Advisors, INC.(1.0291%)
since
2025/06/30
20.
J. Goldman & Co LP(0.9751%)
since
2025/06/30
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.